RE:RE:RE:RE:RE:RE:RE:RE:RE:Hurt shorts: sell your shares for $100Hmmm, as far as I understand Donnatal is a 90 year old drug that still finds 90% approval from customers. It has yet to be seen whether a new competitor will replace it since it has stood the test of time so far. CXR brought on expanded sales force to take advantage of wider acceptance and expecting larger sales targets. AMCo seems to know this business and has a pipeline of new (improved) products and expanding territory that will more than make up for possible declines that may happen for individual products.
Lattice wrote: Adam, Look at actual eps, not adjusted eps. Actual eps is
$0.64. Do you wonder why the adjusted eps is so much greater than actual eps? Drugs are not enduring assets - Donnatal is just one example. Profitable niches can disappear quickly and you are left with the debt, all of a sudden becoming "real" and the added kick of interest on the debt. No company takes on debt, books huge amount of goodwill without R&D, and does not have the intention of price gouging. Pharma that flaunt non-GAAP metrics are being penalized. You may want to read the Barron's article I posted at the beginning of the day, as it explains it well. Or you could just continue blaming it on the shorts as that is easier. ..... Due diligence ... and good night.
adamchess wrote: Is that why Concordia EPS will be more than $6 USD for 2016? That is after interest and taxes.
Lattice wrote: The debt is higher than the assets, by a long shot.
Silverbull13 wrote:
you think this stock is valued at zero??????